Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Huls

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Nature Communications|November 25, 2025
Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
British Journal of Haematology|May 26, 2025
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patientsSjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, et al.
Blood Advances|May 22, 2025
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First RelapseNiek G Van Der Maas, Dimitri A Breems, Clara P W Klerk, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Nature Communications|November 25, 2025
Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
British Journal of Haematology|May 26, 2025
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patientsSjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, et al.
Blood Advances|May 22, 2025
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First RelapseNiek G Van Der Maas, Dimitri A Breems, Clara P W Klerk, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Pageof 4